What to say and how to say it: effective communication for cardiovascular disease prevention
- PMID: 27428113
- PMCID: PMC5045897
- DOI: 10.1097/HCO.0000000000000322
What to say and how to say it: effective communication for cardiovascular disease prevention
Abstract
Purpose of review: Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy.
Recent findings: Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular disease risk, benefits of treatment, and possible adverse effects.
Summary: We propose a four-part model for effective shared decision-making: 1) Assessing patient priorities, perceived risk, and prior experience with cardiovascular risk reduction; 2) Arriving at a recommendation for therapy based on the patient's risk of disease, guideline recommendations, new clinical trial data, and patient preferences; 3) Communicating this recommendation along with risks, benefits, and alternatives to therapy following best practices for discussing numeric risk; and 4) Arriving at a shared decision with the patient with ongoing reassessment as risk factors and patient priorities change.
Conflict of interest statement
AM Navar receives research support from Regeneron and Sanofi pharmaceuticals and consulting fees from Sanofi. SS Martin is listed as a coinventor on a pending patent filed by Johns Hopkins University for a method of low-density lipoprotein cholesterol estimation. He has grant support from the PJ Schafer Cardiovascular Research Fund, American Heart Association, Aetna Foundation, and Google. He has received honoraria from the American College of Cardiology for dyslipidemia-related educational activities. He has served as a consultant to Pressed Juicery, Abbott Nutrition, Quest Diagnostics, and the Pew Research Center. N Stone has no conflicts of interest to declare.
Figures
References
-
- Alston C, Paget L, Halvorson G, et al. Communicating with Patients on Health Care Evidence. 2012 http://nam.edu/wp-content/uploads/2015/06/VSRT-Evidence.pdf.
-
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;63:2889–2934. - PubMed
-
- Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. Journal of the American College of Cardiology. 2015;65:1361–1368. Review of the role of shared decision making in implementation of the lipid guideines. - PMC - PubMed
-
- Samsa GP, Cohen SJ, Goldstein LB, et al. Knowledge of risk among patients at increased risk for stroke. Stroke; a journal of cerebral circulation. 1997;28:916–921. - PubMed
-
- van der Weijden T, van Steenkiste B, Stoffers HE, et al. Primary prevention of cardiovascular diseases in general practice: mismatch between cardiovascular risk and patients’ risk perceptions. Medical decision making: an international journal of the Society for Medical Decision Making. 2007;27:754–761. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
